Longitudinal neuroanatomical and cognitive progression of posterior cortical atrophy by Firth, Nicholas C. et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1093/brain/awz136
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Firth, N. C., Primativo, S., Marinescu, R. V., Shakespeare, T. J., Suarez-Gonzalez, A., Lehmann, M., ... Crutch,
S. J. (2019). Longitudinal neuroanatomical and cognitive progression of posterior cortical atrophy. Brain, 142(7),
2082-2095. https://doi.org/10.1093/brain/awz136
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 12. Sep. 2019
Longitudinal neuroanatomical and cognitive
progression of posterior cortical atrophy
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Posterior cortical atrophy is a clinico-radiological syndrome characterized by progressive decline in visual processing and atrophy
of posterior brain regions. With the majority of cases attributable to Alzheimer’s disease and recent evidence for genetic risk factors
speciﬁcally related to posterior cortical atrophy, the syndrome can provide important insights into selective vulnerability and
phenotypic diversity. The present study describes the ﬁrst major longitudinal investigation of posterior cortical atrophy disease
progression. Three hundred and sixty-one individuals (117 posterior cortical atrophy, 106 typical Alzheimer’s disease, 138 con-
trols) fulﬁlling consensus criteria for posterior cortical atrophy-pure and typical Alzheimer’s disease were recruited from three
centres in the UK, Spain and USA. Participants underwent up to six annual assessments involving MRI scans and neuropsycho-
logical testing. We constructed longitudinal trajectories of regional brain volumes within posterior cortical atrophy and typical
Alzheimer’s disease using differential equation models. We compared and contrasted the order in which regional brain volumes
become abnormal within posterior cortical atrophy and typical Alzheimer’s disease using event-based models. We also examined
trajectories of cognitive decline and the order in which different cognitive tests show abnormality using the same models.
Temporally aligned trajectories for eight regions of interest revealed distinct (P5 0.002) patterns of progression in posterior
cortical atrophy and typical Alzheimer’s disease. Patients with posterior cortical atrophy showed early occipital and parietal
atrophy, with subsequent higher rates of temporal atrophy and ventricular expansion leading to tissue loss of comparable
extent later. Hippocampal, entorhinal and frontal regions underwent a lower rate of change and never approached the extent
of posterior cortical involvement. Patients with typical Alzheimer’s disease showed early hippocampal atrophy, with subsequent
higher rates of temporal atrophy and ventricular expansion. Cognitive models showed tests sensitive to visuospatial dysfunction
declined earlier in posterior cortical atrophy than typical Alzheimer’s disease whilst tests sensitive to working memory impairment
declined earlier in typical Alzheimer’s disease than posterior cortical atrophy. These ﬁndings indicate that posterior cortical atrophy
and typical Alzheimer’s disease have distinct sites of onset and different proﬁles of spatial and temporal progression. The ordering
of disease events both motivates investigation of biological factors underpinning phenotypic heterogeneity, and informs the selec-
tion of measures for clinical trials in posterior cortical atrophy.
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Introduction
Considerable heterogeneity is evident among individuals
with Alzheimer’s disease both clinically (e.g. amnesic,
visual, dysexecutive/behavioural and aphasic presentations
of Alzheimer’s disease) (Galton et al., 2000) and patho-
logically (e.g. hippocampal sparing and limbic-predominant
Alzheimer’s disease subtypes accounting for 25% of cases)
(Murray et al., 2011). This heterogeneity provides an im-
portant opportunity to explore the factors that promote or
inhibit disease progression, both spatially and temporally.
One recent example is the discovery of structural variations
in amyloid-b ﬁbrils between individuals with rapidly and
slowly progressing forms of Alzheimer’s disease (Qiang
et al., 2017). In this context, longitudinal quantitative
tracking of variations in regional tissue damage in large
cohorts of patients with different phenotypic expressions
of a disease can reveal the temporal proﬁles of disease evo-
lution and permit testing of the hypothesis that differen-
tially distributed molecular lesions predict particular
patterns of disease progression.
Perhaps the most striking example of heterogeneity in
Alzheimer’s disease is seen in posterior cortical atrophy
(PCA). PCA is a clinico-radiological syndrome involving a
progressive, dramatic and relatively selective decline in
higher visual processing and other posterior cortical func-
tions (Benson et al., 1988; Crutch et al., 2012). The con-
dition is most commonly associated with the
histopathological features of Alzheimer’s disease, but the
distribution of pathology differs from typical Alzheimer’s
disease. PCA involves prominent tissue loss in the posterior
regions of the brain, with a greater density of neuroﬁbril-
lary tangles (and to a lesser extent, neuritic plaques) in
occipital, posterior parietal and temporo-occipital cortex
and fewer pathological changes in more anterior areas
such as prefrontal cortex (Hof et al., 1990, 1997; Levine
et al., 1993; Ross et al., 1996). A small number of cases of
PCA have been attributed to alternative aetiologies includ-
ing corticobasal degeneration (CBD), Lewy body disease
(LBD), and prion disease (Tang-Wai et al., 2003a, b;
Renner et al., 2004). The prevalence and incidence of
PCA are not known but age of onset is most commonly
in the ﬁfties or sixties (Mendez et al., 2002; Schott et al.,
2016). The atypical, predominantly posterior distribution
of damage in PCA relative to typical Alzheimer’s disease
has been conﬁrmed using a number of structural and func-
tional neuroimaging metrics [e.g. grey matter atrophy
(Lehmann et al., 2011), white matter atrophy and altered
diffusivity (Migliaccio et al., 2012), and cerebral blood ﬂow
(Kas et al., 2011; Lehmann et al., 2016)]. Although certain
molecular pathological metrics show little if any difference
between mild-to-moderately affected PCA and typical
Alzheimer’s disease patients (e.g. widespread amyloid
tracer uptake) (Lehmann et al., 2016), comparable CSF-
amyloid-b42 levels (Ossenkoppele et al., 2015b), the pattern
of tau tracer binding associates strongly with clinical
phenotype (Ossenkoppele et al., 2016). Individuals with
PCA and typical Alzheimer’s disease also show distinct pat-
terns of anti-amyloid-b antibodies (Dorothe´e et al., 2012)
and microglial activation patterns (Kreisl et al., 2017), rais-
ing the possibility that immunological responses could con-
tribute to shaping Alzheimer’s disease phenotypes.
Genetically, apolipoprotein E (APOE) e4 allele status
alters PCA risk but with a smaller effect than for typical
Alzheimer’s disease (Schott et al., 2006; Snowden et al.,
2007) and an exploratory genome-wide association study
has identiﬁed three candidate genetic risk factors that may
be speciﬁc to PCA (Schott et al., 2016).
Understanding the temporal changes associated with neu-
rodegeneration requires longitudinal studies, and to date
there have been no systematic longitudinal studies of
PCA. A small number of longitudinal case reports and
case series have described the clinico-radiological progres-
sion of the condition (Ross et al., 1996; Goethals and
Santens, 2001; Giovagnoli et al., 2009; Kennedy et al.,
2012; Chang et al., 2015; Crutch et al., 2017) or the de-
velopment of speciﬁc cognitive deﬁcits [e.g. dyslexia and
excessive visual crowding (Yong et al., 2016), dysgraphia
(Primativo et al., 2017)]. The only previous longitudinal
group study found comparable rates of widespread grey
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matter loss in patients with PCA and typical Alzheimer’s
disease with a mean disease duration of 5 years, but par-
ticipant numbers were small (17 PCA, 16 typical
Alzheimer’s disease) and the time window limited (1-year
interval) (Lehmann et al., 2012). A large cross-sectional
dataset has been used to make inferences regarding pro-
gression, suggesting an early overlap across Alzheimer’s dis-
ease phenotypes in temporoparietal and posterior cingulate
atrophy and additional involvement of visual association
cortices in PCA, a pattern further emphasized in patients
at later disease stages (Ossenkoppele et al., 2015a).
In this study, we used longitudinal structural imaging and
cognitive proﬁles of individuals with PCA to track long-
term trajectories of change via event-based modelling
(EBM) and differential equation-based approaches.
Continuous trajectories, as well as the ordering of regional
volume loss on structural imaging measures were estimated
for PCA and typical Alzheimer’s disease relative to a con-
trol group. Similar estimations were carried out for trajec-
tories of cognitive decline and ordering of impaired
performance on neuropsychological measures. Our
hypothesis was that atrophy rates would be highest in
phenotype-speciﬁc brain regions early in the disease
course but subsequently show convergence, with atrophy
rates highest across a wider set of contiguous, phenotype
non-speciﬁc but Alzheimer’s disease-relevant networks as
the disease evolves.
Materials and methods
Participants
A ﬂow chart of participants included and excluded from the
overall study and analyses is shown in Fig. 1. The longitudinal
study involved both prospective recruitment from research co-
horts, clinics at specialist centres (January 2005 to December
2016) and retrospective case note review (dating back to
December 1996). One hundred and seventeen individuals
with a clinical diagnosis of PCA were recruited at three spe-
cialist centres: 100 patients at the Dementia Research Centre
(DRC) at the National Hospital for Neurology and
Neurosurgery London (UK), nine patients at the University
Hospital Virgen del Rocio (HUVR) Memory Disorders Unit
(Spain), and eight patients at the University of California San
Francisco (UCSF) Memory and Aging Center (USA). All PCA
patients met both Tang-Wai et al. (2004) and Mendez et al.
(2002) criteria based on available information at baseline and
expert retrospective clinical review. Prospective participants
(n = 10) with clinical features of another neurodegenerative
syndrome (LBD, CBD, prion disease), were excluded (example
features: visual hallucinations, pyramidal signs, reduplicative
phenomena, parkinsonism, alien limb syndrome, asymmetric
dystonia and myoclonus, ataxia); thus all patients included
fulﬁlled consensus criteria for PCA-pure (Crutch et al.,
2017). One hundred and six patients with typical amnestic-
predominant Alzheimer’s disease and 138 healthy individuals
contributed to patient and control reference samples. All pa-
tients with typical Alzheimer’s disease fulﬁlled clinical criteria
for probable Alzheimer’s disease (McKhann et al., 2011); one
prospective participant was found to be carrying a presenilin 1
(PSEN1) mutation and was excluded. All available molecular
or pathological evidence for patients [45/117 (38%) PCA; 49/
106 (46%) typical Alzheimer’s disease] supported underlying
Alzheimer’s disease pathology [73 had a CSF proﬁle compat-
ible with Alzheimer’s disease (Shaw et al., 2009; Duits et al.,
2014) (see Supplementary material for assay-speciﬁc cut-offs);
six had positive amyloid PET scans; 14 had autopsy-proven
Alzheimer’s disease], with the exception of one patient with
PCA found to have a CSF proﬁle borderline compatible with
Alzheimer’s disease (increased amyloid-b1–42 and p-tau,
decreased total-tau). In addition to the patients presented
above, three patients (two PCA, one typical Alzheimer’s dis-
ease) that were initially recruited were excluded from analysis
based on their CSF proﬁle not being compatible with under-
lying Alzheimer’s disease (Duits et al., 2014). Patients with
biomarker evidence of Alzheimer’s disease pathology met the
McKhann et al. (2011) criteria for probable Alzheimer’s dis-
ease with high biomarker probability of Alzheimer’s disease
aetiology (Dubois et al., 2010). Patients with PCA were fol-
lowed-up annually until cognitive and/or physical decline pre-
vented further participation (Fig. 1), together with a reference
subset of typical Alzheimer’s disease and control participants.
Prior ethical approval for the study was provided by the
National Research Ethics Service Committee London Queen
Square and written informed consent was provided by all par-
ticipants according to the Declaration of Helsinki.
See Table 1 for demographic details of participants at initial
visits and for subsets of participants completing follow-up
visits. Of the 361 individuals contributing data to the study,
270 completed at least one neuroimaging assessment and 216
at least one cognitive assessment. From the 270 participants
contributing neuroimaging data, a total of 553 scans gathered
over a maximum period of 6 years were included in the ana-
lysis. From the 216 participants contributing cognitive data, a
total of 419 assessments gathered over a maximum period of 6
years were included in the analysis. Participants were well
matched for age and patient participants were matched for
age at onset at ﬁrst cognitive assessment. There were more
female than male participants in the PCA relative to typical
Alzheimer’s disease group (%male: PCA: 39%; typical
Alzheimer’s disease: 62%; controls: 50%; P50.01). Patient
groups were matched for Mini-Mental State Examination
(MMSE) score at ﬁrst assessment, with both groups signiﬁ-
cantly impaired relative to controls (PCA: 20.88  5.17;
typical Alzheimer’s disease: 19.38  4.85; controls:
29.02  0.98).
Procedures
T1-weighted volumetric magnetic resonance scans were
acquired on ﬁve different scanners [two 3T Trio (DRC and
UCSF), 1.5 T Intera (HUVR), and two 1.5 Signa units (DRC)]
using spoiled gradient recalled or gradient echo (MPRAGE)
sequences. The scans consisted of full brain coverage coronal
or sagittal slices running between 124 and 208 contiguous
slices of 1.5 or 1.0mm. Full details of imaging parameters
are shown in the Supplementary material, and site and scanner
distribution in earlier and later PCA are shown in the
Supplementary material.
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To estimate regional brain volumes, we used the Geodesic
Information Flows (GIF) algorithm (Cardoso et al., 2012) to
perform tissue segmentation and parcellation. The
Neuromorphometrics atlas was used for segmentation, which
produced 144 different brain regions of interest across the left
and right hemisphere. Segmentation failed for six scans belong-
ing to ﬁve subjects (three controls, one PCA and one typical
Alzheimer’s disease) due to motion artefacts; these scans were
subsequently removed and not included in the statistics in
Table 1. Brain volumes were corrected for total intracranial
volume (TIV), age and gender, scanner type (1.5 T, 3T) and
site (DRC, UCSF, HUVR) using a general linear model, where
gender, scanner type and site were encoded using one-hot
encoding. A total of 52 brain regions of interest were removed
(18 were not part of the cerebral cortex, six had segmentation
errors, 28 were grouped into larger regions of interest). Left
and right brain regions were averaged into one region, provid-
ing a total of 46 regions of interest, which were further
averaged into eight regions of interest corresponding to
whole brain, hippocampal, occipital, frontal, entorhinal, tem-
poral (excluding hippocampal), parietal and ventricle volumes.
Participants in the prospective study phase completed an
annual battery of neuropsychological tests. This general neuro-
psychological battery (see Lehmann et al., 2011 for detailed
references) includes standard tests of general cognitive function
(Supplementary Table 1). Individual test administration was
discontinued at subsequent visits for participants scoring at
ﬂoor, in which case a ﬂoor score was assigned for this test
at next assessment, with scores at all following assessments
classiﬁed as missing data.
Statistical analysis
The differential equation model (DEM) (Villemagne et al.,
2013) was used to estimate long-term neuroanatomical and
cognitive biomarker trajectories from multiple short-term
Figure 1 Study flow chart showing participants included and excluded from analyses. Study participants were recruited from three
different centres from the Dementia Research Centre (DRC), University of California San Francisco (UCSF) and University Hospital Virgen del
Rocio (HUVR). Of all the study participants, some underwent neuroimaging (Table 1) and neuropsychological testing (Table 1 and Supplementary
Table 1). We performed statistical analysis both longitudinally, using the differential equation model (DEM) and cross-sectionally, using the EBM.
Full results are also shown in the Supplementary material on the subset of patients with molecular and pathological evidence of Alzheimer’s
disease pathology. AD = Alzheimer’s disease; tAD = typical Alzheimer’s disease; DLB = dementia with Lewy bodies; CBD = corticobasal degen-
eration; MMSE = Mini-Mental State Examination.
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longitudinal data. For each region of interest or cognitive test
the DEM calculates the rate of change for each individual
across each of the visits (Fig. 2A). The rate of change of a
biomarker was assumed to be a function of the mean bio-
marker value for each participant. In order to make minimal
assumptions on the subsequent trajectory shape, a non-
parametric Gaussian process regression model was then ﬁt to
all of the participants’ values to give an average rate of change
for all biomarker values (Fig. 2B). This function was then
integrated, giving an average biomarker value as a function
of time (Fig. 2C). With no reliable means of measuring age
at onset, biomarker trajectories were aligned by deﬁning a
reference time t0 (t = 0; Fig. 2D) as the threshold that best
separated controls from patients. See the Supplementary ma-
terial for full DEM method. All participants with more than
one assessment were included in these analyses.
To estimate disease progression from limited datasets and to
validate the DEM trajectories, we used the EBM (Fonteijn
et al., 2012). The EBM derives a probabilistic ordering in
which biomarkers show detectable abnormality. The most
likely sequence provides a staging system expressing the most
likely position of a subject along the most likely sequence of
events. In this work, two formulations of the EBM were used
corresponding to MRI brain volume data and cognitive test
data. For the EBMs using MRI data, the previously published
formulation of the model was used. For cognitive data models
of normal and abnormal biomarker distributions were repre-
sented using kernel density estimation instead of simple para-
metric distributions used previously in the EBM. See
Supplementary material for complete formulations of both
EBMs. All available data at baseline visit were included in
these analyses.
For DEM results, we tested for differences in estimated bio-
marker values between time points (10, 0, and 10 years from
t0) both within- and between-group. Within-group differences
in estimated biomarker values were assessed using two-tailed
paired t-tests for all pairs of biomarkers (e.g. within PCA,
values of biomarker i versus biomarker j for all i,j) at 10,
0, and 10 years since t0. Between-group (PCA versus typical
Alzheimer’s disease) differences in estimated biomarker values
were assessed using two-tailed two sample t-tests for all bio-
markers at each time point. For EBM results, we tested for
statistically signiﬁcant differences in the estimated abnormality
sequences, both within and between groups. Non-parametric
tests were used because of non-Gaussianity of the data (data
are ordinal representing ranks) and samples were thinned (1
every 100) as adjacent samples in Markov Chain Monte Carlo
(MCMC) sampling are correlated. Within-group differences
were assessed using Wilcoxon signed-rank one-tailed tests for
all pairs of biomarkers (i,j), which assesses whether biomarker
i becomes abnormal before biomarker j. Signiﬁcant differences
in the relative position of a biomarker within the EBM abnor-
mality sequence between groups (PCA versus typical
Alzheimer’s disease) were assessed using two-tailed Mann-
Whitney U-tests. We applied Bonferroni-corrected thresholds
for all tests performed on EBM and DEM results.
Data availability
The data that support the ﬁndings of this study are available
from the corresponding author, upon reasonable request. All
the algorithms used in the present paper are reported in the
Supplementary material.
Results
To give the reader a sense of the raw neuroimaging data,
we show in Fig. 3 longitudinal data for two exemplar
metrics—occipital and hippocampal atrophy. Compared
to patients with typical Alzheimer’s disease, PCA patients
showed more occipital (PCA: mean volume
Table 1 Demographic details for participants in the study contributing neuroimaging and neuropsychological data
Total study participants
PCA (n = 117) Typical Alzheimer’s disease (n = 106) Controls (n = 138)
Visits Number
of
subjects
Age (SD) Gender
(M:F)
Age at
onset
(SD)
Number
of
subjects
Age Gender
(M:F)
Age at
onset
(SD)
Number
of
subjects
Age (SD) Gender
(M:F)
Age at
onset
(SD)
Neuroimaging
51 89 63.52 (6.91) 55:34 58.50 (6.86) 66 66.39 (8.58) 31:35 61.71 (8.37) 115 61.87 (10.43) 70:45 -
52 46 62.11 (6.52) 29:17 58.15 (6.58) 37 66.84 (8.83) 17:20 62.38 (8.52) 50 61.00 (12.01) 31:19 -
53 31 62.75 (6.50) 19:12 59.16 (6.67) 21 71.00 (6.97) 10:11 65.86 (7.45) 28 65.75 (5.96) 16:12 -
54 15 61.46 (4.44) 11:4 58.73 (4.61) 14 70.89 (6.33) 8:6 66.93 (6.67) 17 66.82 (4.88) 10:7 -
55 9 61.73 (4.06) 7:2 58.56 (4.72) 4 72.08 (4.81) 3:1 68.75 (4.87) 8 66.11 (4.83) 3:5 -
56 2 62.35 (1.65) 1:1 58.50 (1.50) 1 79.90 (0.00) 1:0 76.00 (0.00) 115 61.87 (10.43) 70:45 -
Neuropsychology
51 109 64.49 (7.54) 41:68 59.99 (8.08) 58 65.68 (7.57) 36:22 54.74 (4.93) 49 63.12 (5.90) 12:37 -
52 70 63.64 (7.32) 23:47 59.35 (7.72) 28 64.58 (7.08) 13:15 54.08 (4.78) 18 60.00 (5.87) 0:18 -
53 45 62.73 (7.26) 16:29 58.70 (7.53) 5 66.08 (2.78) 2:3 56.00 (0.00) 0 - - -
54 20 63.19 (7.00) 7:13 59.84 (6.46) 0 - - - 0 - - -
55 7 59.44 (4.84) 2:5 56.25 (4.62) 0 - - - 0 - - -
56 2 57.22 (3.49) 1:1 55.32 (1.32) 0 - - - 0 - - -
Details are presented at initial visit (in bold) and for subsets of participants who completed follow-up assessments (up to a maximum of six). Number of individuals at each
assessment, mean (and standard deviation, SD) age, gender and mean age at onset (and standard deviation) are shown per number of visits. F = female; M = male.
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z-score = 3.74; typical Alzheimer’s disease: 1.33,
P51  109) and less hippocampal atrophy (PCA: z-
score = 0.74; typical Alzheimer’s disease: z = 2.09,
P51  104) at baseline.
Temporally-aligned average DEM trajectories for eight
regions of interest were calculated for participants with
PCA (Fig. 4A) and typical Alzheimer’s disease (Fig. 4B).
Conﬁdence estimates using bootstraps for each average tra-
jectory were also calculated (Fig. 5). Amongst patients with
PCA, occipital and parietal atrophy was most evident
before t0, and by t0 we also observe considerable atrophy
in the temporal lobe. Across the 10 years following t0, we
observe a marked increase in the rate of occipital, parietal
and temporal atrophy and ventricular expansion. By con-
trast, hippocampal, entorhinal and frontal atrophy never
match the extent of tissue loss in posterior and temporal
regions. More than 10 years from t0, atrophy rates in oc-
cipital, parietal and temporal lobes seem to slow down, but
limited data in this time window prevent the drawing of
any clear conclusions.
By contrast, before t0 patients with typical Alzheimer’s
disease showed most extensive tissue loss in the hippocam-
pus, with subsequent rates of change highest for temporal
atrophy and ventricular expansion. It should be noted that
within 12 years from t0, model estimates of parietal and
ventricular abnormality amongst patients with typical
Alzheimer’s disease are equivalent to or exceed the relative
extent of hippocampal abnormality. Comparing PCA and
typical Alzheimer’s disease trajectories directly at t0 (Fig. 5),
the estimated region of interest volumes were lower in pos-
terior regions (parietal: P5 1  106; occipital:
P5 2  103) in PCA relative to typical Alzheimer’s pa-
tients overall. On the other hand, participants with PCA
had higher hippocampal and entorhinal estimated volumes
(both P5 1  109) and lower ventricular volume
(P5 2  103) compared to patients with typical
Alzheimer’s disease. Comparison of estimated frontal or
temporal region of interest volumes at t0 did not ﬁnd evi-
dence of differences between patient groups following
Bonferroni correction (both P4 2  103). For a summary
Figure 2 Diagram of the differential equation model. (A) Measuring biomarker rate of change from line of best fit. The biomarker
measurements for each subject were plotted against time since baseline, and a line was fit for each subject independently. The slope of these lines
was then used as a measure of the biomarker rate of change. (B) Rate of change model. The slopes of each fitted line were plotted against the
average biomarker value of each subject (blue crosses). A non-parametric model (Gaussian process regression, green line) was then fitted on
measurements, which gave a model prediction and also a 95% confidence interval. (C) Trajectory reconstruction. A line integral was performed
on the rate of change model from B. The integration limits were defined as the biomarker values where the corresponding change is zero or at
the limits of the data. Starting from the upper integration limit, the trajectory was reconstructed from the rate of change prediction, which
represents the slope corresponding to that biomarker value. Before integration, an arbitrary starting time point, t0 = 0, was defined, thus all time
is relative to t0. (D) Anchoring process. In the absence of a reliable estimate of time since disease onset, the origin t0 was set as the point that best
separates controls from patients, which have been staged along the time axis using their biomarker data. Moreover, to make trajectories
comparable across biomarkers we convert the biomarker values to Z-scores with respect to controls, which results in a scaling along the y-axis.
The process (A–D) was repeated for each biomarker independently. After fitting each biomarker, the subjects can be staged along the disease
timeline, as in (D), using the trajectories from all biomarkers.
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of the statistical tests including comparisons 10 years
before and following t0, see Supplementary Table 9.
Differences between PCA and typical Alzheimer’s disease
progression are also recapitulated with the EBM. Figure 4C
and D shows, for both PCA and typical Alzheimer’s dis-
ease, snapshots of brain atrophy at model stages 4, 8, 16,
24, 32, 40, and 46 (of 46) generated from the positional
variance diagrams (Supplementary Fig. 1). Patients with
PCA showed early atrophy in occipital (inferior, anterior,
superior, lateral) and superior parietal areas, whilst patients
with typical Alzheimer’s disease showed early atrophy in
the amygdala, hippocampus and entorhinal cortex, fol-
lowed by temporal areas. The ordering is largely preserved
under bootstrapping and supported by statistical testing
(Supplementary Figs 2 and 3). Comparing PCA and typical
Alzheimer’s disease abnormality sequences provided evi-
dence of differences in ordering of disease events between
patient groups (Supplementary Table 9). Most occipital
Figure 3 Observed longitudinal occipital (A–D) and hippocampal (E–H) atrophy, relative to controls, for PCA (left) and typical
Alzheimer’s disease patients (right). (A–B and E–F) Spaghetti plots anchored at baseline visit. (C–D and G–H) Hairy line plots for observed
longitudinal data anchored to the group trajectory using the baseline value. tAD = typical Alzheimer’s disease.
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regions were estimated to become abnormal signiﬁcantly
earlier in PCA compared to typical Alzheimer’s disease,
with the exception of the occipital pole, which was esti-
mated to become abnormal earlier in typical Alzheimer’s
disease. Temporal, frontal, hippocampus and entorhinal re-
gions were estimated to become abnormal signiﬁcantly ear-
lier in typical Alzheimer’s disease compared to PCA. There
was mixed evidence of parietal regions differing in
estimated ordering of abnormality between patient
groups. For example, superior parietal and precuneus re-
gions were estimated to become abnormal signiﬁcantly ear-
lier in PCA and typical Alzheimer’s disease, respectively,
although test effect sizes were small. Full statistical testing
can be found in Supplementary Fig. 4.
A summary of all available baseline cognitive data is
shown in Supplementary Table 1. A number of MMSE
Figure 4 Region of interest trajectories and ordering of atrophy. (A and B) Trajectories of different region of interest volumes from the
DEM for (A) PCA progression and (B) typical Alzheimer’s disease (AD) progression. The x-axis shows the number of years since t0, and the y-axis
shows the Z-score of the region of interest volume relative to controls. The trajectories of the ventricles have been flipped to aid comparison.
Overlaid are histograms of subject stages based on the estimated trajectories. (C and D) Ordering of atrophy in (C) PCA patients and (D) typical
Alzheimer’s disease patients according to the EBM. White regions are within the volume range of healthy controls, while red regions are abnormal
by the corresponding stage, with shading indicating the probability of abnormality. By stage k, a number of k biomarkers shaded in red became
abnormal. For positional variance diagrams used to generate brain figures and full details on methodology, see the Supplementary material.
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scores were available in typical Alzheimer’s disease partici-
pants who did not undergo the full neuropsychological as-
sessment (n = 31), but are included for disease staging
purposes. Both patient groups showed evidence of dimin-
ished performance on all of the available cognitive meas-
ures relative to controls. The two patient groups had
comparable scores on MMSE, visual episodic memory
and working memory. Nonetheless, consistent with stand-
ard phenotypic descriptions, notable cognitive patterns
could be observed as differences in performance between
the two groups. Overall, PCA patients exhibited signiﬁ-
cantly poorer performance in numeracy, basic vision,
space and object perception relative to their typical
Alzheimer’s disease counterparts. Overall, patients with
typical Alzheimer’s disease had a lower performance in
verbal episodic memory compared to PCA patients.
To evaluate the cognitive changes due to disease, an EBM
maximum likelihood sequence of biomarker abnormality
was estimated for both PCA and typical Alzheimer’s disease
using 13 cognitive test baseline measures (Fig. 6A and B).
Uncertainty in these orderings was estimated using a boot-
strapping procedure (Supplementary Fig. 5) (Young et al.,
2014). Patients with PCA showed early impairment on per-
ceptual, spatial, numeracy (GDA subtraction) and working
memory tasks (digit span backwards). Patients with typical
Alzheimer’s disease showed early deﬁcits in working
memory, verbal episodic memory and numeracy (addition
and subtraction), with impairment on visual tasks a
consistently later feature (4/5 visual/visuomotor tasks oc-
cupying the latest positions in the sequence). The most not-
able differences between the PCA and typical Alzheimer’s
disease maximum likelihood sequences were the occurrence
of the spatially demanding A cancellation time measure
(PCA: event 4/13; typical Alzheimer’s disease: event 13/
13; P5 7  104) and the working memory measure of
digit span forwards (PCA: event 13/13; typical
Alzheimer’s disease: event 1/13; P5 7  104). These
measures were selected as exemplar cognitive tasks; corres-
ponding individual observed longitudinal data outline the
variability of longitudinal performance on cognitive meas-
ures (Fig. 7). Compared to patients with typical Alzheimer’s
disease, PCA patients showed signiﬁcantly poorer A cancel-
lation (PCA: z-score = 10.91; typical Alzheimer’s disease:
5.03; P5 1  105) and comparable digit span forward
performance (PCA: z-score = 1.10; typical Alzheimer’s
disease: z = 1.48; P4 0.05). Differences between PCA
and typical Alzheimer’s disease sequences of cognitive
changes were also statistically signiﬁcant (Supplementary
Figs 7 and 8).
Average trajectories for 13 cognitive measures were cal-
culated for participants with PCA (Fig. 6C). Trajectories
for typical Alzheimer’s disease were not calculated due to
insufﬁcient follow-up visits from these participants.
Conﬁdence estimates for each average trajectory were
also calculated (Supplementary Fig. 11). Fragmented letters,
dot counting and A cancellation metrics showed greatest
Figure 5 Mean trajectories for region of interest volumes for PCA and typical Alzheimer’s disease aligned on the same
temporal scale with samples from the posterior distribution showing the confidence of the mean trajectory. The x-axis shows the
number of years since t0, and the y-axis shows the z-score of the region of interest volume relative to controls. The trajectories for the ventricles
have been flipped to aid visual comparison. AD = Alzheimer’s disease.
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impairment at t0. These measures also showed the greatest
subsequent rates of change, likely reﬂecting both progres-
sion of cognitive impairment but also the psychometric
properties of the tests. A second cluster of tasks showing
comparable rates of decline included MMSE, shape dis-
crimination, object decision and visual and verbal episodic
memory. Of the remaining tasks, working memory meas-
ures showed later impairment and lower rates of decline.
Discussion
This ﬁrst major longitudinal investigation of disease pro-
gression in PCA revealed distinct patterns of tissue loss as
compared to typical Alzheimer’s disease. Following the
early neuroanatomical signature of occipital and parietal
atrophy characterized in previous cross-sectional studies,
individuals with PCA underwent further atrophy in those
regions as well as temporal lobe atrophy and ventricular
expansion. These changes were commensurate in relative
extent with occipital and parietal damage within an esti-
mated 10 years of t0. By contrast, entorhinal, hippocampal
and frontal regions underwent a lower rate of change
which, whilst notably abnormal, did not result in the rela-
tive magnitude of loss seen even initially in the key
posterior regions. Although in PCA there was markedly
greater parietal than hippocampal atrophy throughout the
disease course, the reverse was not true for typical
Alzheimer’s disease; in these individuals the relative extent
of parietal atrophy matched that of the hippocampal re-
gions within 11 years of t0.
Overall, ﬁndings are consistent with a space of continu-
ous phenotypic variability across the full spectrum of
Alzheimer’s disease, as is increasingly being recognized
both clinically (Dickerson et al., 2011) and pathologically
(Murray et al., 2011; Whitwell et al., 2012).
The ﬁndings of this study support the idea that the spa-
tial and temporal proﬁles of PCA and typical Alzheimer’s
disease phenotypes may be the consequence of insults ori-
ginating at different sites within a common disease-relevant
network of brain regions (Warren et al., 2013). Findings
suggest selective intracortical vulnerability, with early
abnormalities estimated for some (e.g. occipital: inferior/su-
perior/middle/fusiform) but not all regions (occipital pole)
for the PCA group overall, consistent with relative preser-
vation of visual acuity in PCA (Lehmann et al., 2011).
Regions considered key sites of pathological activity in
Alzheimer’s disease, such as the entorhinal cortex and
hippocampus, exhibit neuroanatomical distinctions between
PCA and typical Alzheimer’s disease; such distinctions are
Figure 6 (A and B) Positional variance diagrams for (A) PCA and (B) typical Alzheimer’s disease showing estimated order of
impairment on 14 cognitive metrics (y-axis) across different stages (positions on x-axis). Each entry (x,y) represents the probability of
a particular cognitive metric becoming abnormal at a given position in the sequence (darker shades = higher probability). (C) Trajectories of
different cognitive tests from the differential equation model for PCA progression. The x-axis shows the number of years since t0, and the y-axis
shows the z-score on each cognitive test relative to controls. Overlaid are also the histograms of the subjects, as they have been staged by the
model.
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evident not only early in the disease, but throughout the
disease course. Accordingly, serious consideration must be
given to whether trajectories are dictated by a combination
of site of origin, relevant connectivity and time, or alterna-
tively by protective factors which reduce the vulnerability
of certain networks. For example, between 0 and 10 years
from t0, PCA subjects revealed more pronounced extent
and rate of atrophy overall and within phenotype-speciﬁc
regions of interest compared to typical Alzheimer’s disease,
which suggest that factors other than site of origin or brain
connectivity might also be involved. Similarly, the longitu-
dinal clinical data and model-based estimation of change
over a near 30-year window mean such distinctions cannot
be dismissed as minor variations in early disease expres-
sion, as could have been argued or hypothesized previously
from solely cross-sectional data.
A key strength of the study is the ability to compare and
contrast atrophy and cognitive change between individuals
Figure 7 Observed longitudinal data from example cognitive tasks. Observed longitudinal A cancellation (A–D) and digit span for-
wards (E–H) scores, relative to controls, for PCA (left) and typical Alzheimer’s disease patients (right). (A–B and E–F) Spaghetti plots anchored at
baseline visit. (C–D and G–H) Hairy line plots for observed longitudinal data anchored to the group trajectory using the baseline value.
tAD = typical Alzheimer’s disease.
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with PCA and typical Alzheimer’s disease. The DEM can
infer long-term progression from short-term longitudinal
data, which is critical in the case of a sporadic syndrome
like PCA, which is relatively rare and cannot practically be
identiﬁed and followed in asymptomatic individuals. The
DEM, unlike the EBM, includes time in the model to
permit the estimation of rates of change, although the ap-
proach can only integrate the rate of change to a trajectory
of data where the modelled average rate of change does not
alternate between increasing and decreasing. Another
unique advantage of this study is the EBM’s capacity to
estimate longitudinal patterns from sufﬁcient, representative
cross-sectional data.
The results on neuropsychological data highlight differ-
ences and similarities between patients with PCA and typ-
ical Alzheimer’s disease in terms of both early cognitive
difﬁculties and trajectories. At the early stages both patient
groups demonstrated widespread cognitive decline com-
pared to controls and the two groups did not differ in
terms of MMSE, working memory and visual episodic
memory, which might be comparably impaired but with
different underlying cognitive mechanisms. The differences
between the two groups included lower performance in nu-
meracy, visuoperceptual and visuospatial processing in
PCA relative to typical Alzheimer’s disease. In contrast,
lower performance in verbal episodic memory was
observed in typical Alzheimer’s disease compared to PCA
patients. The different pattern of results observed for visual
and verbal episodic memory suggest that the former involve
an important component of visual processing and might
represent an unreliable measure of episodic memory in
PCA. Longitudinally, the data highlighted different trajec-
tories of decline for different cognitive domains in the two
groups of patients. Among the most striking differences,
performance on measures sensitive to visuospatial process-
ing (such as the A cancellation test) was estimated to de-
cline early in PCA and relatively late in typical Alzheimer’s
disease. Conversely, performance on measures of working
memory (such as the forward digit span) were estimated to
decline early in typical Alzheimer’s disease and late in PCA.
An apparently unexpected result may relate to the back-
ward digit span being estimated as becoming abnormal
relatively early in PCA. The backward digit span is
indeed a measure of working memory. Nonetheless, the
recent literature on cognitive psychology and neuroimaging
suggests that the backward digit span is a complex cogni-
tive test, which requires the activation of multiple cognitive
systems and brain circuits. In particular, the prominent
contribution of visuospatial imagery and the high activa-
tion of the dorsolateral prefrontal cortex have been shown
(Rapport et al., 1994; Reynolds et al., 1997; Hoshi et al.,
2000; Hilbert et al., 2014). The literature thus seems to
suggest that caution must be placed when interpreting the
cognitive processes underlying this test, since cognitive
functions other than working memory, some of which are
already known to be impaired in PCA, might cause a de-
cline in performance.
While the current study represents the largest longitu-
dinal investigation of PCA to date comprising analyses of
structural imaging and comprehensive neuropsychological
measures, several limitations should be noted. Owing to
the relative rarity of PCA, data were acquired over an ex-
tended time period; for the majority of this period (from
1996 onwards), evidence for underlying Alzheimer’s disease
pathology was only routinely available at autopsy.
Correspondingly, amyloid PET imaging and CSF were
only available in a proportion of patients, with non-
Alzheimer’s disease aetiologies (DLB, CBD) ruled out
based on available clinical information. Nevertheless, re-
peating analyses on the subset of patients with evidence
of underlying Alzheimer’s disease pathology generated ﬁnd-
ings that were consistent with overall results
(Supplementary Figs 9–17). Another limitation of our
study is that imaging data were acquired on different scan-
ners of different strengths, although these covariates were
regressed out after the estimation of regional brain vol-
umes. Moreover, another limitation is the comparatively
small amount of data collected from sites outside of the
UCL Dementia Research Centre, thus limiting our under-
standing of PCA outside of this centre. Imbalanced num-
bers from different sites is a limitation in many multicentre
studies, in particular in studies in which cognitive tests are
administered in different languages. Controlling for differ-
ences across centres becomes increasingly challenging with
smaller numbers in speciﬁc centres as unintended variance
may be removed by regressing out differences between cen-
tres. We hope that improvements in the diagnosis of PCA
will promote more studies spanning different countries and
socioeconomic areas, and more large-scale analyses to in-
corporate these data. While numbers of time points varied
between participants, the EBM and DEM approaches out-
lined above enabled the estimation of ordering of disease
events and non-linear trajectories based on cross-sectional
and participant-speciﬁc short-term longitudinal data. These
approaches have characteristic assumptions that are im-
portant to consider when interpreting the current ﬁndings.
First of all, the DEM estimates every trajectory independ-
ently, so after DEM ﬁtting we need to put multiple trajec-
tories on a common axis, which also requires normalization
and a time anchor. Here we used the threshold that best
separates controls from patients to anchor the time (t = 0).
The DEM trajectories are also susceptible to ﬂoor and ceil-
ing effects in both brain volumes and cognitive measures,
but the probabilistic nature of the DEM goes some way to
ameliorating this. With regards to the EBM, it assumes
trajectories are step-functions, where biomarkers switch
from a normal to an abnormal value. Finally, both the
EBM and DEM estimate a population-average disease pro-
gression, which is not necessarily indicative of how each
individual will progress.
Future studies will need to focus on disentangling the
genetic, pathological, molecular and neurodevelopmental
factors responsible for the distinction in long-term disease
pathways and progression reported in this paper. For
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example, pilot genome-wide association study ﬁndings in
PCA implicate genes associated with intercellular commu-
nication, signalling pathways related to retinal degeneration
and the development of the visual system, but these results
must be replicated in larger samples and the impacts of
heterogeneity and young age at onset be further disambig-
uated. Building on the insights of the landmark investiga-
tions 20 years ago (Hof et al., 1997, 1990),
neuropathological studies must also examine the relative
impact of disease upon speciﬁc neuronal populations and
different inﬂammatory processes. It is hoped that better
understanding the causes of phenotypic heterogeneity in
Alzheimer’s disease may prove a catalyst for novel thera-
peutic strategies.
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